Cardiol Therapeutics (CT9) Ratios
Cardiol Therapeutics Ratios
DE:CT9's free cash flow for Q2 2026 was $-4.38M. For the 2026 fiscal year, DE:CT9's free cash flow was decreased by $-3.03K and operating cash flow was $-4.38M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.16 | 4.52 | 4.36 | 6.27 | 7.53 |
| Quick Ratio | 4.16 | 4.52 | 4.36 | 6.27 | 7.53 |
| Cash Ratio | 3.79 | 4.36 | 4.21 | 6.07 | 7.25 |
| Solvency Ratio | -5.87 | -5.09 | -3.30 | -1.15 | -2.11 |
| Operating Cash Flow Ratio | -4.22 | -3.58 | -0.00 | -2.78 | -2.04 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -759.21 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 17.76M | $ 24.53M | $ 27.70M | $ 51.61M | $ 75.50M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.32 | 1.29 | 1.30 | 1.19 | 1.15 |
| Debt Service Coverage Ratio | 0.00 | -1099.83 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.62 | 0.84 | 1.25 | 1.93 | 2.18 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | -49091.93% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | -48812.06% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -57736.32% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -40170.45% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -31391.46% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -40170.45% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 37.25% | 78.15% |
| EBT Per EBIT | 98.55% | 91.06% | 94.44% | 61.44% | 69.58% |
| Return on Assets (ROA) | -143.18% | -115.11% | -76.64% | -18.58% | -28.13% |
| Return on Equity (ROE) | -189.17% | -148.32% | -99.58% | -22.07% | -32.43% |
| Return on Capital Employed (ROCE) | -191.02% | -162.05% | -104.86% | -96.39% | -59.59% |
| Return on Invested Capital (ROIC) | -190.61% | -161.62% | -104.86% | -35.87% | -46.54% |
| Return on Tangible Assets | -143.18% | -115.11% | -77.08% | -18.66% | -28.26% |
| Earnings Yield | -29.68% | -27.70% | -39.67% | -26.72% | -24.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 |
| Payables Turnover | 0.00 | 0.05 | 0.00 | 0.03 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -6825.01 | 0.00 | -13857.77 | 1886.76 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 1886.76 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 6825.01 | 0.00 | 13857.77 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 1886.76 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.27 | -0.35 | -0.00 | -0.44 | -0.54 |
| Free Cash Flow Per Share | -0.27 | -0.35 | -0.00 | -0.44 | -0.55 |
| Dividend Paid and CapEx Coverage Ratio | -974.30 | -1177.12 | -391.54 | -364.35 | -1823.38 |
| Capital Expenditure Coverage Ratio | -974.30 | -1177.12 | -391.54 | -364.35 | -1823.38 |
| Operating Cash Flow Coverage Ratio | -190.04 | -158.08 | -0.16 | -373.54 | -200.30 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -299.02 |
| Free Cash Flow Yield | -20.95% | -18.94% | -0.04% | -63.29% | -23.40% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.36 | -3.63 | -2.52 | -3.74 | -4.07 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 1278.68 |
| Price-to-Book (P/B) Ratio | 6.37 | 5.35 | 2.51 | 0.83 | 1.32 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.77 | -5.28 | -2808.87 | -1.58 | -4.27 |
| Price-to-Operating Cash Flow Ratio | -4.78 | -5.28 | -2816.05 | -1.58 | -4.28 |
| Price-to-Earnings Growth (PEG) Ratio | 0.14 | -0.23 | -0.02 | 0.05 | 0.23 |
| Enterprise Value Multiple | -2.71 | -2.81 | -1.30 | 0.53 | -0.44 |
| Enterprise Value | 92.66M | 101.98M | 36.14M | -16.27M | 16.93M |
| EV to EBITDA | -2.71 | -2.81 | -1.30 | 0.53 | -0.44 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 214.93 |
| EV to Free Cash Flow | -3.88 | -4.07 | -1431.43 | 0.60 | -0.72 |
| EV to Operating Cash Flow | -3.88 | -4.07 | -1435.08 | 0.60 | -0.72 |
| Tangible Book Value Per Share | 0.21 | 0.35 | 0.43 | 0.83 | 1.76 |
| Shareholders’ Equity Per Share | 0.21 | 0.35 | 0.44 | 0.84 | 1.76 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.63 | 0.22 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.39 | -0.51 | -0.44 | -0.18 | -0.57 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.37 | 0.78 |
| Interest Burden | 0.99 | 1.00 | 1.00 | 1.00 | 0.82 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 138.02 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 353.90 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 107.90 |
| Income Quality | 0.71 | 0.68 | 0.00 | 0.88 | 0.74 |
Currency in CAD
